Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorDittner-Moormann, Sabine
dc.contributor.authorReschke, Madlen
dc.contributor.authorAbbink, Floor
dc.contributor.authorAerts, Isabelle
dc.contributor.authorAtalay, Hatice Tuba
dc.contributor.authorFedorovna Bobrova, Nadezhda
dc.contributor.authorSábado Álvarez, Constantino
dc.date.accessioned2022-06-02T08:43:47Z
dc.date.available2022-06-02T08:43:47Z
dc.date.issued2021-06
dc.identifier.citationDittner‐Moormann S, Reschke M, Abbink FCH, Aerts I, Atalay HT, Fedorovna Bobrova N, et al. Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). Pediatr Blood Cancer. 2021 Jun;68(6):e28963.
dc.identifier.issn1545-5017
dc.identifier.urihttp://hdl.handle.net/11351/7617
dc.descriptionChemotherapy; Childhood cancer; Radiotherapy
dc.description.abstractIntroduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of retinoblastoma cells beyond the natural limits of the eye is related to a high mortality. Adjuvant therapy after enucleation has been shown to prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary and there is no unifying consensus on the optimal choice of treatment. Method Data on guidelines for adjuvant treatment in European retinoblastoma referral centres were collected in an online survey among all members of the European Retinoblastoma Group (EURbG) network. Extended information was gathered via personal email communication. Results Data were collected from 26 centres in 17 countries. Guidelines for adjuvant treatment were in place at 92.3% of retinoblastoma centres. There was a consensus on indication for and intensity of adjuvant treatment among more than 80% of all centres. The majority of centres use no adjuvant treatment for isolated focal choroidal invasion or prelaminar optic nerve invasion. Patients with massive choroidal invasion or postlaminar optic nerve invasion receive adjuvant chemotherapy, while microscopic invasion of the resection margin of the optic nerve or extension through the sclera are treated with combined chemo- and radiotherapy. Conclusion Indications and adjuvant treatment regimens in European retinoblastoma referral centres are similar but not uniform. Further biomarkers in addition to histopathological risk factors could improve treatment stratification. The high consensus in European centres is an excellent foundation for a common European study with prospective validation of new biomarkers.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesPediatric Blood & Cancer;68(6)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectRetina - Càncer - Quimioteràpia
dc.subjectRetina - Càncer - Radioteràpia
dc.subjectEnquestes
dc.subject.meshRetinoblastoma
dc.subject.meshCombined Modality Therapy
dc.subject.meshRisk Factors
dc.subject.meshSurveys and Questionnaires
dc.titleAdjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/pbc.28963
dc.subject.decsretinoblastoma
dc.subject.decstratamiento combinado
dc.subject.decsfactores de riesgo
dc.subject.decsencuestas y cuestionarios
dc.relation.publishversionhttps://doi.org/10.1002/pbc.28963
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Dittner-Moormann S] Department of Pediatric Hematology and Oncology, University Duisburg-Essen, University Hospital Essen, Essen, Germany. [Reschke M] Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany. [Abbink FCH] Amsterdam UMC, Location VU University Medical Centre, Amsterdam, The Netherlands. [Aerts I] Institut Curie, PSL Research University and University of Paris, Paris, France. [Atalay HT] Gazi University School of Medicine, Ankara, Turkey. [Fedorovna Bobrova N] Filatov Eye Institute Odessa, Odessa, Ukraine. [Sábado Álvarez C] Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid33720495
dc.identifier.wos000628887900001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record